C11 peptide-1
C11 peptide-1 is an antifibrotic agent that binds directly to Collagen I. C11 peptide-1 physically disrupts Collagen I interaction with Lumican. C11 peptide-1 reduces inflammatory infiltration and inhibits the ERK1/2 and Smad2/3 signaling pathways. C11 peptide-1 can be used for the research of liver fibrosis.
For research use only. We do not sell to patients.
- Formula: C69H106N18O25S2
- Molecular Weight:1651.82
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
ERK1 |
ERK2 |
C11 peptide-1 (10 μM; 1 h) potently inhibits the human Lumican-Collagen I protein interaction with a 75.99% inhibition rate[1].
C11 peptide-1 (3.125-100 μM) binds directly to purified Collagen I with stronger affinity than peptide C5[1].
C11 peptide-1 (10 μM; 24 h) significantly reduces TGF-β1-induced Collagen I (COL1A1) expression in human LX2 hepatic stellate cells[1].
C11 peptide-1 (10 μM; 24 h) significantly reduces TGF-β1-induced α-SMA expression, a marker of activation, in human LX2 hepatic stellate cells[1].
C11 peptide-1 (10 μM; 24 h) significantly inhibits TGF-β1-induced proliferation of human LX2 hepatic stellate cells[1].
C11 peptide-1 (10 μM; 24 h) significantly reduces TGF-β1-induced Collagen I fluorescence intensity in human LX2 hepatic stellate cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human LX2 hepatic stellate cells (TGF-β1-stimulated)
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Significantly suppressed TGF-β1-induced COL1A1 expression with a statistically significant reduction (P < 0.01) relative to the TGF-β1-only treated group.
Showed superior inhibitory efficacy to peptide C5.\nSignificantly inhibited TGF-β1-induced α-SMA expression with a statistically significant reduction (P < 0.01) relative to the TGF-β1-only treated group.
-
Cell Line:human LX2 hepatic stellate cells (TGF-β1-stimulated)
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Significantly reduced the ratio of EdU-positive LX2 cells with a statistically significant reduction (P < 0.01) relative to the TGF-β1-only treated group.
-
Cell Line:human LX2 hepatic stellate cells (TGF-β1-stimulated)
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Visually and quantitatively reduced COL1A1 fluorescence intensity with a statistically significant reduction (P < 0.01) relative to the TGF-β1-only treated group.
| Species | Dose | Route | T1/2 | Cmax | MRT0-inf | AUC0-t | AUC0-inf |
|---|---|---|---|---|---|---|---|
| Rat[1] | 1.0 mg/kg | i.p. | 0.4 h | 878.47 ng/mL | 0.67 h | 809.49 ng·h/mL | 815.38 ng·h/mL |
Peptide C11 (1.0 mg/kg; i.p.; single dose) exhibits favorable pharmacokinetic properties in male Sprague-Dawley rats, with a T1/2 of 0.4 h and an AUC0-inf of 815.38 h × ng/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 6-8 weeks old, 20-24 g, CCl4-induced liver fibrosis)[1]
-
Dosage:150 μg/kg
-
Administration:i.p.; daily; 3 weeks
-
Result:Reversed the CCl4-induced decrease in body weight.
Produced a significant reduction in serum ALT and AST levels.
Significantly decreased hepatic hydroxyproline content.
Reduced inflammatory infiltration and collagen deposition as observed via H&E and PSR staining.
Significantly downregulated hepatic expression of key fibrosis markers including Collagen I, α-SMA, and Timp1.
Significantly decreased phosphorylation levels of ERK1/2 and Smad2/3.
-
Animal Model:Sprague-Dawley (male)[1]
-
Dosage:1.0 mg/kg
-
Administration:i.p.; single dose
-
Result:Demonstrated a half-life (t1/2) of 0.4 h.
Reached a maximum concentration (Cmax) of 878.47 ng/mL.
Achieved a mean residence time (MRT0-inf) of 0.67 h.
Exhibited an area under the curve from time zero to the last measurable concentration (AUC0-t) of 809.49 h × ng/mL.
Exhibited an area under the curve from time zero to infinity (AUC0-inf) of 815.38 h × ng/mL.
Chemical Information
-
Molecular Weight 1651.82
-
Formula C69H106N18O25S2
-
Sequence
Cys-Tyr-Leu-Asp-Asn-Asn-Lys-Ile-Cys-Asn-Ile-Pro-Asp-Glu (Disulfide bridge: Cys1-Cys9)
-
Sequence Shortening
CYLDNNKICNIPDE (Disulfide bridge: Cys1-Cys9)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
C11 peptide-1 Related Classifications
HY-P11827 Related Classifications
Powered by Bioz